Rapacuronium

From Self-sufficiency
Jump to: navigation, search
Rapacuronium
250px
Systematic (IUPAC) name
(2β,3α,5α,16β,17β)-3-(acetyloxy)-16-(1-allylpiperidinium-1-yl)-2-piperidin-1-yl-17-(propionyloxy)androstane bromide
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
Legal status
Legal status
  • Withdrawn (U.S)
Pharmacokinetic data
Bioavailability Not applicable
Protein binding Variable
Metabolism Hydrolyzed to active metabolites
CYP system not involved
Biological half-life 141 minutes (mean)
Excretion Renal and fecal
Identifiers
CAS Number 156137-99-4
ATC code none
PubChem CID 5311398
Synonyms [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
Chemical data
Formula C37H61N2O4Script error: No such module "String".
Molar mass 597.891 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001.[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


fr:Rapacuronium
  1. Shapse, Deborah (March 27, 2001). Voluntary Market WithdrawalPDF (10.8 KiB). Organon International. Retrieved on 2007-04-02.